AARTIDRUGS437.00

Aarti Drugs Ltd.

· Pharma & Health
₹ CrorePeersALIVUSAARTIPHARMADVENZYMESAGARWALEYEAKUMSAPLLTDCORONAHCGMcap ₹3,988 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Inventory Days (DIO)112.82120.02119.10119.10
Receivable Days (DSO)101.70114.86118.08118.08
Payable Days (DPO)98.80105.60115.97107.93
Cash Conversion Cycle (days)115.72129.28121.21129.25
Working Capital Turnover4.814.764.704.91
Asset Turnover1.040.930.910.91
Cash Conversion (CFO/Net Income)2.091.451.301.30
CFO/EBITDA1.130.850.820.82
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.